IMAGENEBIO files 8-K with new November 2025 presentation

Rhea-AI Filing Summary

IMAGENEBIO, INC. (IMA) filed a current report to announce that it has updated its corporate presentation for use in meetings with investors, analysts and other interested parties. The updated presentation, dated November 19, 2025, is being made available on the company’s website and is also included as Exhibit 99.1 to this report.

The company notes that the information in this investor presentation and in this report under Item 7.01 is being furnished rather than filed under securities laws, which means it is not automatically incorporated into other securities filings unless specifically referenced there.

NASDAQ false 0001835579 0001835579 2025-11-19 2025-11-19

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 19, 2025

IMAGENEBIO, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-40287		81-1697316
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

12526 High Bluff Drive, Suite 345
San Diego, California		92130
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (858) 345-6265

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value		IMA		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01. Regulation FD Disclosure.

On November 19, 2025, the Company updated its corporate presentation for use in meetings with investors, analysts and others. The presentation is being pubished on the Company’s website and a copy is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein.

The information in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or incorporated by reference in any filing under the Securities Act of 1933, as amended, unless expressly incorporated by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number		Description
99.1		Corporate Presentation of the Company Dated November 19, 2025
104		Cover Page Interactive Data File (embedded with the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				IMAGENEBIO, INC.
Date: November 19, 2025				By:		/s/ Kristin Yarema
						Kristin Yarema, Ph.D.
						Chief Executive Officer

FAQ

What did IMAGENEBIO, INC. (IMA) announce in this 8-K filing?

IMAGENEBIO, INC. announced that it has updated its corporate presentation for use in meetings with investors, analysts and others, and has made the presentation available on its website and as Exhibit 99.1.

What is included as Exhibit 99.1 in IMAGENEBIO (IMA)'s 8-K?

Exhibit 99.1 contains the company’s corporate presentation dated November 19, 2025, which summarizes information IMAGENEBIO plans to use in investor and analyst meetings.

Is the IMAGENEBIO (IMA) investor presentation considered filed with the SEC?

No. The company states that the information in Item 7.01 of this report, including Exhibit 99.1, is furnished and not deemed filed under the Exchange Act, unless specifically incorporated by reference in another filing.

Where can investors find IMAGENEBIO (IMA)'s updated corporate presentation?

The updated corporate presentation is being published on IMAGENEBIO’s website and is also available as Exhibit 99.1 to this Form 8-K.

Who signed this IMAGENEBIO (IMA) 8-K report?

The report was signed on behalf of IMAGENEBIO, INC. by Kristin Yarema, Ph.D., who serves as the company’s Chief Executive Officer.

What other exhibit is referenced in IMAGENEBIO (IMA)'s 8-K?

In addition to the investor presentation, the filing references Exhibit 104, described as the Cover Page Interactive Data File embedded within the Inline XBRL document.